SCHEMBL2908995

SCHEMBL2908995

COc1ccc(-c2ccc(C(c3c[nH]nc3-c3ccco3)N3CCOCC3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.46
SMAD3 P84022 2/20 0.45
P4HB P07237 1/20 0.45
ALDH1A1 P00352 8/20 0.43
HPGD P15428 2/20 0.43
TP53 P04637 1/20 0.41
MAPT P10636 4/20 0.40
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
POLB P06746 1/20 0.39
TSHR P16473 2/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905924 0.90 OPRD1 (0.40) BRAFSMAD3P4HBALDH1A1HPGD
SCHEMBL2903266 0.88 P4HB (0.41) P4HBALDH1A1MAPTPOLBLMNA
SCHEMBL2902229 0.86 SMN1; SMN2 (0.47) SMAD3ALDH1A1HPGDMAPTKDM4E
SCHEMBL2902824 0.85 MAPT (0.47) ALDH1A1HPGDTP53MAPTMAPK1
SCHEMBL2901677 0.84 MAPT (0.39) BRAFSMAD3P4HBALDH1A1HPGD
SCHEMBL2902613 0.84 PIK3R1 (0.37) P4HBALDH1A1HPGDTP53MAPT
SCHEMBL2905003 0.84 SIRT1 (0.38) SMAD3P4HBALDH1A1HPGDTP53
SCHEMBL2908989 0.82 KMT2A (0.44) ALDH1A1MAPTKDM4ETSHRMEN1
SCHEMBL2904844 0.78 OPRD1 (0.40) P4HBMAPTPOLBLMNAMEN1
Morpholine SCHEMBL2905731 0.77 OPRD1 (0.35) P4HBTP53MAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A BRAF 1942/4885SMAD3 4051/4885P4HB 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.